236 related articles for article (PubMed ID: 34424409)
1. Novel and Promising Systemic Treatment Approaches in Mesothelioma.
Dudnik E; Reinhorn D; Holtzman L
Curr Treat Options Oncol; 2021 Aug; 22(10):89. PubMed ID: 34424409
[TBL] [Abstract][Full Text] [Related]
2. Malignant mesothelioma: Advances in immune checkpoint inhibitor and mesothelin-targeted therapies.
Hu ZI; Ghafoor A; Sengupta M; Hassan R
Cancer; 2021 Apr; 127(7):1010-1020. PubMed ID: 33620732
[TBL] [Abstract][Full Text] [Related]
3. Emerging biological therapies for the treatment of malignant pleural mesothelioma.
Davis AP; Kao SC; Clarke SJ; Boyer M; Pavlakis N
Expert Opin Emerg Drugs; 2021 Jun; 26(2):179-192. PubMed ID: 33945357
[No Abstract] [Full Text] [Related]
4. Novel therapies for malignant pleural mesothelioma.
Scherpereel A; Wallyn F; Albelda SM; Munck C
Lancet Oncol; 2018 Mar; 19(3):e161-e172. PubMed ID: 29508763
[TBL] [Abstract][Full Text] [Related]
5. [Research Progress of Immune Checkpoint Inhibitors
in Malignant Pleural Mesothelioma].
Huang Y; Meng Q
Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):441-446. PubMed ID: 34157803
[TBL] [Abstract][Full Text] [Related]
6. [Anti-tumor immunotherapy in malignant pleural mesothelioma].
Scherpereel A; Willemin MC; Wasielewski E; Dhalluin X
Rev Mal Respir; 2018 Apr; 35(4):465-476. PubMed ID: 29415822
[TBL] [Abstract][Full Text] [Related]
7. A catalogue of treatment and technologies for malignant pleural mesothelioma.
Schunselaar LM; Quispel-Janssen JM; Neefjes JJ; Baas P
Expert Rev Anticancer Ther; 2016; 16(4):455-63. PubMed ID: 26943000
[TBL] [Abstract][Full Text] [Related]
8. The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma.
Perera ND; Mansfield AS
Curr Oncol Rep; 2022 Nov; 24(11):1413-1423. PubMed ID: 35657483
[TBL] [Abstract][Full Text] [Related]
9. Searching for targets for the systemic therapy of mesothelioma.
Stahel RA; Weder W; Felley-Bosco E; Petrausch U; Curioni-Fontecedro A; Schmitt-Opitz I; Peters S
Ann Oncol; 2015 Aug; 26(8):1649-60. PubMed ID: 25722383
[TBL] [Abstract][Full Text] [Related]
10. A review of bevacizumab in the treatment of malignant pleural mesothelioma.
Brosseau S; Assoun S; Naltet C; Steinmetz C; Gounant V; Zalcman G
Future Oncol; 2017 Dec; 13(28):2537-2546. PubMed ID: 29086616
[TBL] [Abstract][Full Text] [Related]
11. New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.
Tsao AS; Pass HI; Rimner A; Mansfield AS
J Clin Oncol; 2022 Feb; 40(6):681-692. PubMed ID: 34985934
[TBL] [Abstract][Full Text] [Related]
12. Patterns of failure following surgical resection for malignant pleural mesothelioma.
Jänne PA; Baldini EH
Thorac Surg Clin; 2004 Nov; 14(4):567-73. PubMed ID: 15559064
[TBL] [Abstract][Full Text] [Related]
13. Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?
Signorelli D; Macerelli M; Proto C; Vitali M; Cona MS; Agustoni F; Zilembo N; Platania M; Trama A; Gallucci R; Ganzinelli M; Pelosi G; Pastorino U; de Braud F; Garassino MC; Lo Russo G
Tumori; 2016; 102(1):18-30. PubMed ID: 26481865
[TBL] [Abstract][Full Text] [Related]
14. Systemic treatments for mesothelioma: standard and novel.
Kindler HL
Curr Treat Options Oncol; 2008 Jun; 9(2-3):171-9. PubMed ID: 18770046
[TBL] [Abstract][Full Text] [Related]
15. Breaking through the treatment desert of conventional mesothelin-targeted CAR-T cell therapy for malignant mesothelioma: A glimpse into the future.
Wang Y; Zhao G; Xing S; Wang S; Li N
Pharmacol Res; 2024 Jun; 204():107220. PubMed ID: 38768670
[No Abstract] [Full Text] [Related]
16. New horizons from novel therapies in malignant pleural mesothelioma.
Sayan M; Mamidanna S; Fuat Eren M; Daliparty V; Zoto Mustafayev T; Nelson C; Ohri N; Jabbour SK; Guven Mert A; Atalar B
Adv Respir Med; 2020; 88(4):343-351. PubMed ID: 32869268
[TBL] [Abstract][Full Text] [Related]
17. [Malignant pleural mesothelioma: 2013 state of the art].
Campbell K; Brosseau S; Reviron-Rabec L; Bergot E; Lechapt E; Levallet G; Zalcman G
Bull Cancer; 2013 Dec; 100(12):1283-93. PubMed ID: 24225007
[TBL] [Abstract][Full Text] [Related]
18. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.
Cui W; Popat S
Drugs; 2021 Jun; 81(9):971-984. PubMed ID: 34106454
[TBL] [Abstract][Full Text] [Related]
20. New therapeutic strategies for malignant pleural mesothelioma.
Bonelli MA; Fumarola C; La Monica S; Alfieri R
Biochem Pharmacol; 2017 Jan; 123():8-18. PubMed ID: 27431778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]